Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | NCK1 | P16333 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16284370 | 0.86 | CYP1A2 (0.57) | CYP1A2NCK1BACE1CYP2A6ALDH1A1 | |
| SCHEMBL12570780 | 0.85 | CYP1A2 (0.55) | CYP1A2NCK1BACE1CYP2A6ALDH1A1 | |
| SCHEMBL1724199 | 0.82 | CYP1A2 (0.57) | CYP1A2NCK1BACE1CYP2A6ALDH1A1 | |
| SCHEMBL3652540 | 0.82 | CYP1A2 (0.57) | CYP1A2NCK1BACE1CYP2A6ALDH1A1 | |
| SCHEMBL204054 | 0.82 | CYP1A2 (0.57) | CYP1A2NCK1BACE1CYP2A6ALDH1A1 | |
| SCHEMBL12824284 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2A6ALDH1A1KDM4EMAPT | |
| SCHEMBL18122875 | 0.78 | HDAC1 (0.46) | CYP1A2NCK1BACE1KDM4EMAPT | |
| SCHEMBL5050008 | 0.78 | BACE1 (0.53) | CYP1A2BACE1CYP2A6ALDH1A1KDM4E | |
| SCHEMBL9022559 | 0.78 | PDE10A (0.46) | BACE1CYP2A6ALDH1A1PDE3BPDE3A | |
| SCHEMBL7454652 | 0.78 | KDM4E (0.58) | NCK1BACE1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235753-A2 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-3247702-B1 | PESTICIDALLY ACTIVE SEMI-CARBAZONES AND THIOSEMICARBAZONES DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-04-22 | — | — | EP | disclosed |
| WO-2016156076-A1 | PESTICIDALLY ACTIVE CARBAMOYLATED AND THIOCARBAMOYLATED OXIME DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-10-06 | — | — | WO | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2015154169-A1 | BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-15 | — | — | WO | disclosed |
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120039847-A1 | Hepatitis C Virus Inhibitors | ZHAO SHU-HAI (CN) | 2012-02-16 | — | — | US | disclosed |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | BORNHOP DARRYL J | 2008-10-02 | — | — | US | disclosed |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | BORNHOP DARRYL J | 2008-10-02 | — | — | US | disclosed |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | VANDERBILT UNIVERSITY | 2008-10-02 | — | — | US | disclosed |
| US-7338651-B2 | Multi-use multimodal imaging chelates | TEXAS TECH UNIVERSITY SYSTEM (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338651-B2 | Multi-use multimodal imaging chelates | TEXAS TECH UNIVERSITY SYSTEM (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1438318-B1 | TISSUE SPECIFIC FLUORESCENT CHELATES | UNIV TEXAS TECH (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6962690-B2 | Tissue specific fluorescent chelates possessing long wavelength UV excitation | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1438318-A1 | TISSUE SPECIFIC FLUORESCENT CHELATES | Texas Tech University (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030099598-A1 | Tissue specific fluorescent chelates possessing long wavelength UV excitation | DOW GLOBAL TECHNOLOGIES INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003035655-A1 | TISSUE SPECIFIC FLUORESCENT CHELATES | TEXAS TECH UNIVERSITY (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099598-A1 | Tissue specific fluorescent chelates possessing long wavelength UV excitation | DDB1, TNNC1, TRPC1 | CYP1A2 4388/4885NCK1 4373/4885BACE1 3011/4885 |
| US-20120039847-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, LIPC | CYP1A2 985/4885NCK1 1229/4885BACE1 4203/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | CYP1A2 2027/4885NCK1 1161/4885BACE1 723/4885 |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | CYP1A2 4559/4885NCK1 4079/4885BACE1 3210/4885 |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | CYP1A2 4559/4885NCK1 4079/4885BACE1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.